A clinical trial to learn more about the effects of DII235 in people with high levels of lipoprotein(a)

You may be able to join if

• Signed informed consent must be obtained prior to participation in the study.
• Male or female participants 18 to 80 years of age (inclusive) at the screening.
• Lp(a) ≥ 150 nmol/L at screening, measured at the central laboratory.
• Presence of ASCVD and/or Type 2 diabetes mellitus (T2DM). Diagnosis of ASCVD should be based on at least one of the following: a. Coronary heart disease (CHD): • Prior myocardial infarction (MI) of presumed atherosclerotic origin, which occurred ≥ 12 weeks prior to the Screening Visit • Prior coronary revascularization (PCI or CABG) that occurred ≥ 12 weeks prior to the Screening Visit • Angiographic or CT-imaging (e.g., MDCT/CTA) evidence of coronary atherosclerosis: ≥50% stenosis in at least one major epicardial coronary artery • Coronary artery calcium (CAC) score of ≥ 300 AU by computed tomography (if a participant has T2DM CAC score of ≥ 100 AU is sufficient to define ASCVD) And/or b. Cerebrovascular disease (CeVD): • Prior ischemic stroke, which occurred ≥ 12 weeks prior to the Screening Visit, confirmed by documented brain imaging (CT or MRI); embolic stroke (not of atherosclerotic origin) is not a qualifying event. • History of percutaneous or surgical carotid artery revascularization that occurred ≥ 12 weeks prior to the Screening Visit • Carotid artery stenosis ≥ 70% or symptomatic carotid artery disease with ≥ 50% carotid arterial stenosis on prior angiography or ultrasound And/or c. Peripheral arterial disease (PAD): • Prior non-traumatic amputation of a lower extremity due to peripheral artery disease • History of prior percutaneous or surgical revascularization of iliac, femoral, or popliteal artery • Prior documentation of a resting ankle-brachial index ≤ 0.9 On standard of care treatment for ASCVD risk factors (according to local guidelines and per Investigator discretion). Participants receiving lipid lowering therapy (including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody inhibitors must be on a stable regimen per local guidelines prior to screening, with no planned changes made after screening, and expected to remain on a stable regimen through the end of the treatment (as statins may raise Lp(a) concentrations). A stable dose is defined as at least 8 weeks of treatment at a consistent dose level for monoclonal antibody PCSK9 inhibitors, and at least 4 weeks for all other LLT.